These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18520311)

  • 1. Medicaid prior authorization and controlled-release oxycodone.
    Morden NE; Zerzan JT; Rue TC; Heagerty PJ; Roughead EE; Soumerai SB; Ross-Degnan D; Sullivan SD
    Med Care; 2008 Jun; 46(6):573-80. PubMed ID: 18520311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002.
    Zerzan JT; Morden NE; Soumerai S; Ross-Degnan D; Roughead E; Zhang F; Simoni-Wastila L; Sullivan SD
    Med Care; 2006 Nov; 44(11):1005-10. PubMed ID: 17063132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
    Fischer MA; Schneeweiss S; Avorn J; Solomon DH
    N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
    Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
    J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
    Katz MH; Kotabe S
    Med Care; 2008 Sep; 46(9):1002. PubMed ID: 18725857
    [No Abstract]   [Full Text] [Related]  

  • 8. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-controlled analgesia versus oral controlled-release oxycodone - are they interchangeable for acute postoperative pain after laparoscopic colorectal surgeries?
    Ho HS
    Oncology; 2008; 74 Suppl 1():61-5. PubMed ID: 18758200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
    Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
    J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.
    Roughead EE; Zhang F; Ross-Degnan D; Soumerai S
    Med Care; 2006 Apr; 44(4):378-82. PubMed ID: 16565640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
    Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
    Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence.
    Potter JS; Hennessy G; Borrow JA; Greenfield SF; Weiss RD
    Drug Alcohol Depend; 2004 Nov; 76(2):213-5. PubMed ID: 15488345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cluster analysis of state Medicaid prescription drug benefit programs based on potential determinants of per capita drug expenditure.
    Roy S; Madhavan SS
    Res Social Adm Pharm; 2009 Mar; 5(1):51-62. PubMed ID: 19285289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a Medicaid prior authorization policy for pregabalin.
    Margolis JM; Johnston SS; Chu BC; Onukwugha E; Hvidsten K; Alvir J; Rossi JG; Mullins CD
    Am J Manag Care; 2009 Oct; 15(10):e95-102. PubMed ID: 19817512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in opioid consumption in the Nordic countries 2002-2006.
    Hamunen K; Paakkari P; Kalso E
    Eur J Pain; 2009 Oct; 13(9):954-62. PubMed ID: 19091608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful interventions in decreasing oxycodone CR prescriptions within an underserved population.
    Shah NR; Haddad-Lacle J; Hogan T
    J Opioid Manag; 2015; 11(6):481-8. PubMed ID: 26728645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled-release oxycodone-induced seizures.
    Klein M; Rudich Z; Gurevich B; Lifshitz M; Brill S; Lottan M; Weksler N
    Clin Ther; 2005 Nov; 27(11):1815-8. PubMed ID: 16368452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.